Carl June, MD, University of Pennsylvania, and his colleagues, will present the findings of a clinical trial today in which nine of twelve leukemia patients who received infusions of their own genetically engineered T cells responded to the therapy and several of them remain cancer-free. The breakthrough therapy was advanced, in large part, by The Leukemia & Lymphoma Society (LLS). LLS has invested more than $16 million in this work. LLS has funded Dr. June in various capacities since 1998 (and we just awarded him a new 5-year $6.25 million grant which will bring our investment to $21 million); other members of his team began receiving LLS funding as far back as 1992. Bloomberg News reported on this study today and credits LLS with funding the work. Further, UPENN credits LLS funding with playing a significant role in the partnership announced between UPENN and Novartis this summer to advance this work.